Abrahams Brett

Fondateur chez

Heppinn Biosciences

Health Technology

Consumer Services

Finance

Profil

Abrahams Brett is the founder of Heppinn Biosciences, which was founded in 2020.
Currently, Dr. Brett serves as an advisory board member for Accelerator Services Corp, Foundation for Angelman Syndrome Therapeutics, and Cureshank.
Dr. Brett previously held positions as Senior Director at Ovid Therapeutics, Inc. in 2018 and as Executive Vice-President at Magnolia Neurosciences Corp.
from 2018 to 2022.
Dr. Brett received an undergraduate degree from Queen's University in 1997 and a doctorate degree from the University of British Columbia in 2004.

Postes actifs de Abrahams Brett

Sociétés	Poste	Début
Accelerator Services Corp Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements.	Consultant / Advisor	01/02/2022
Heppinn Biosciences	Fondateur	01/11/2020
Foundation for Angelman Syndrome Therapeutics Foundation for Angelman Syndrome Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides angelman syndrome treatment services	Consultant / Advisor	01/09/2022
Cureshank Cureshank The private company is located in the US. Its mission is to accelerate the development of effective treatments by bridging the translational research gap between basic SHANK3 science and clinical application. Cureshank identifies, funds, and supports strategic research projects addressing critical barriers such as epilepsy, developmental regression, and other comorbidities associated with PMS. Key initiatives include the Cureshank Biomarkers and Outcome Measures Consortium, which develops standardized clinical trial tools and facilitates regulatory approval. The organization organizes patient-focused drug development activities, including an FDA externally-led meeting and the creation of a comprehensive PMS conceptual model cataloging nearly 100 symptoms. Cureshank promotes early genetic testing through its Start Genetic campaign and shares real family stories to raise awareness of the condition’s challenges. It provides resources for researchers and industry, including access to genetic data, patient-derived biosamples, animal models, curated funding opportunities, and a webinar series. Cureshank supports and facilitates patient participation in clinical trials and natural history studies worldwide and relies on donations and community fundraising events to sustain its programs. Cureshank is a nonprofit organization founded by parents of children affected by Phelan-McDermid syndrome (PMS) and other SHANK-related neurodevelopmental disorders.	Consultant / Advisor	01/09/2019

Tous les postes actifs de Abrahams Brett

Anciens postes connus de Abrahams Brett

Sociétés	Poste	Fin
Magnolia Neurosciences Corp. Magnolia Neurosciences Corp. BiotechnologyHealth Technology Engages in research and development of drugs	Private Equity Investor	28/02/2022
OVID THERAPEUTICS INC.	Directeur/Membre du Conseil	30/08/2018

Voir l'expérience en détail de Abrahams Brett

Formation de Abrahams Brett

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Abrahams Brett

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	8
Ovid Therapeutics, Inc. Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders	Health Technology
Queen's University Queen's University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Accelerator Services Corp Accelerator Services Corp Investment ManagersFinance Accelerator Services invests in companies located in the United States. The firm focuses on the healthcare sector. It provides financing for early stage capital requirements.	Finance
Foundation for Angelman Syndrome Therapeutics Foundation for Angelman Syndrome Therapeutics Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides angelman syndrome treatment services	Commercial Services
Magnolia Neurosciences Corp. Magnolia Neurosciences Corp. BiotechnologyHealth Technology Engages in research and development of drugs	Health Technology
Heppinn Biosciences
Cureshank Cureshank The private company is located in the US. Its mission is to accelerate the development of effective treatments by bridging the translational research gap between basic SHANK3 science and clinical application. Cureshank identifies, funds, and supports strategic research projects addressing critical barriers such as epilepsy, developmental regression, and other comorbidities associated with PMS. Key initiatives include the Cureshank Biomarkers and Outcome Measures Consortium, which develops standardized clinical trial tools and facilitates regulatory approval. The organization organizes patient-focused drug development activities, including an FDA externally-led meeting and the creation of a comprehensive PMS conceptual model cataloging nearly 100 symptoms. Cureshank promotes early genetic testing through its Start Genetic campaign and shares real family stories to raise awareness of the condition’s challenges. It provides resources for researchers and industry, including access to genetic data, patient-derived biosamples, animal models, curated funding opportunities, and a webinar series. Cureshank supports and facilitates patient participation in clinical trials and natural history studies worldwide and relies on donations and community fundraising events to sustain its programs. Cureshank is a nonprofit organization founded by parents of children affected by Phelan-McDermid syndrome (PMS) and other SHANK-related neurodevelopmental disorders.